TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.
Tenshin H, Teramachi J, Oda A, Amachi R, Hiasa M, Bat-Erdene A, Watanabe K, Iwasa M, Harada T, Fujii S, Kagawa K, Sogabe K, Nakamura S, Miki H, Kurahashi K, Yoshida S, Aihara K, Endo I, Tanaka E, Matsumoto T, Abe M.
Tenshin H, et al. Among authors: aihara k.
Blood Adv. 2017 Oct 26;1(24):2124-2137. doi: 10.1182/bloodadvances.2017008813. eCollection 2017 Nov 14.
Blood Adv. 2017.
PMID: 29296860
Free PMC article.